Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation

Women with rheumatoid arthritis (RA) are often of childbearing age and therefore questions regarding reproductive health and the use of medications, including disease-modifying anti-rheumatic drugs (DMARDs) may arise during the clinical consultation. Each patient requires individual assessment in or...

Full description

Bibliographic Details
Main Authors: Ngian, G., Briggs, Andrew, Ackerman, I., Van Doornum, S.
Format: Journal Article
Published: 2016
Online Access:http://hdl.handle.net/20.500.11937/36249
_version_ 1848754715877179392
author Ngian, G.
Briggs, Andrew
Ackerman, I.
Van Doornum, S.
author_facet Ngian, G.
Briggs, Andrew
Ackerman, I.
Van Doornum, S.
author_sort Ngian, G.
building Curtin Institutional Repository
collection Online Access
description Women with rheumatoid arthritis (RA) are often of childbearing age and therefore questions regarding reproductive health and the use of medications, including disease-modifying anti-rheumatic drugs (DMARDs) may arise during the clinical consultation. Each patient requires individual assessment in order to effectively manage the disease while minimizing any treatment-associated risks to the fetus. Although good-quality controlled trials are lacking, there is an increasing volume of evidence surrounding the use of immunosuppressive therapies in pregnancy and lactation. This review summarizes the currently available information which can be of benefit to clinicians guiding patients and their families through the risks and benefits of continuing RA therapy during pregnancy and lactation. Further studies and ongoing surveillance of drug safety in pregnancy are required to resolve the uncertainties that remain regarding synthetic and biologic DMARDs.
first_indexed 2025-11-14T08:44:49Z
format Journal Article
id curtin-20.500.11937-36249
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T08:44:49Z
publishDate 2016
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-362492019-02-19T05:35:35Z Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation Ngian, G. Briggs, Andrew Ackerman, I. Van Doornum, S. Women with rheumatoid arthritis (RA) are often of childbearing age and therefore questions regarding reproductive health and the use of medications, including disease-modifying anti-rheumatic drugs (DMARDs) may arise during the clinical consultation. Each patient requires individual assessment in order to effectively manage the disease while minimizing any treatment-associated risks to the fetus. Although good-quality controlled trials are lacking, there is an increasing volume of evidence surrounding the use of immunosuppressive therapies in pregnancy and lactation. This review summarizes the currently available information which can be of benefit to clinicians guiding patients and their families through the risks and benefits of continuing RA therapy during pregnancy and lactation. Further studies and ongoing surveillance of drug safety in pregnancy are required to resolve the uncertainties that remain regarding synthetic and biologic DMARDs. 2016 Journal Article http://hdl.handle.net/20.500.11937/36249 10.1111/1756-185X.12860 fulltext
spellingShingle Ngian, G.
Briggs, Andrew
Ackerman, I.
Van Doornum, S.
Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation
title Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation
title_full Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation
title_fullStr Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation
title_full_unstemmed Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation
title_short Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation
title_sort safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation
url http://hdl.handle.net/20.500.11937/36249